Nonhuman IAPP Variants Inhibit Human IAPP Aggregation

Author(s): Alissa Oakes, Kate Menefee, Arleen Lamba, Larry M. Palato, Dillon J. Rinauro, Angela Tun, Betssy Jauregui, Kevin Chang, Luiza A. Nogaj, David A. Moffet*

Journal Name: Protein & Peptide Letters

Volume 28 , Issue 9 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Aim: To identify naturally occurring variants of IAPP capable of inhibiting the aggregation of human IAPP and protecting living cells from the toxic effects of human IAPP.

Background: The loss of insulin-producing β-cells and the overall progression of type 2 diabetes appears to be linked to the formation of toxic human IAPP (hIAPP, Islet Amyloid Polypeptide, amylin) amyloid in the pancreas. Inhibiting the initial aggregation of hIAPP has the potential to slow, if not stop entirely, the loss of β-cells and halt the progression of the disease.

Objective: To identify and characterize naturally occurring variants of IAPP capable of inhibiting human IAPP aggregation.

Methods: Synthetic human IAPP was incubated with synthetic IAPP variants identified from natural sources under conditions known to promote amyloid-based aggregation. To identify IAPP variants capable of inhibiting human IAPP aggregation, Thioflavin T-binding fluorescence, atomic force microscopy, and cell-rescue assays were performed.

Results: While most IAPP variants showed little to no ability to inhibit human IAPP aggregation, several variants showed some ability to inhibit aggregation, with two variants showing substantial inhibitory potential.

Conclusion: Several naturally occurring IAPP variants capable of inhibiting human IAPP aggregation were identified and characterized.

Keywords: Islet amyloid polypeptide, protein aggregation, amyloid, type 2 diabetes, amylin, pancreas.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 25 August, 2021
Page: [963 - 971]
Pages: 9
DOI: 10.2174/0929866528666210806152706
Price: $65

Article Metrics

PDF: 260